• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性红斑狼疮患者住院的发生率及危险因素:霍普金斯狼疮队列的前瞻性研究

Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort.

作者信息

Petri M, Genovese M

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

出版信息

J Rheumatol. 1992 Oct;19(10):1559-65.

PMID:1464868
Abstract

OBJECTIVE

To determine the incidence of and risk factors for hospitalization in systemic lupus erythematosus (SLE).

METHOD

A prospective study of hospitalizations in 1989 and 1990 in the Hopkins Lupus Cohort was conducted.

RESULTS

Of 261 patients with SLE in the Hopkins Cohort, 147 (56.3%) were hospitalized in 1989 or 1990. The incidence of hospitalization was 0.69 admissions/person-year. The mean length of stay was 9.6 days +/- 12.7 (SD). Activity of SLE accounted for 35% of admissions. Risk factors for hospitalization for active lupus in 1990 included activity of SLE in 1989 (measured by either the highest physician's global assessment in 1989, p = 0.004, highest lupus activity index (LAI) score in 1989, p = 0.002, or highest systemic lupus erythematosus disease activity index score in 1989, p = 0.008), an average prednisone dose greater than 10 mg in 1989 (p = 0.002), and the presence of neurologic lupus in 1989 (p = 0.02). Medical admissions other than for active SLE accounted for an additional 27% of admissions; one-half of these admissions (47%) were for complications of SLE and/or its treatment, with coronary artery disease the most common (21% of medical admissions). Infections were responsible for 14% of admissions. The majority of infections were bacterial (90%). Risk factors for hospitalization for infection in 1990 included active SLE in 1989 (p = 0.03), average prednisone dose of greater than 10 mg in 1989 (p = 0.04), immunosuppressive drug use in 1989 (p = 0.003), neurologic SLE in 1989 (p = 0.02) and previous hospitalization in 1989 (p = 0.03).

CONCLUSION

Hospitalization is common in the Hopkins Lupus Cohort, with active SLE (35%), infection (14%, infection and/or active SLE; 11%, infection alone) and medical complications of SLE (13%) as the 3 most common causes.

摘要

目的

确定系统性红斑狼疮(SLE)患者住院的发生率及危险因素。

方法

对霍普金斯狼疮队列1989年和1990年的住院情况进行前瞻性研究。

结果

在霍普金斯队列的261例SLE患者中,147例(56.3%)在1989年或1990年住院。住院发生率为0.69次入院/人年。平均住院时间为9.6天±12.7(标准差)。SLE活动导致35%的入院。1990年活动性狼疮住院的危险因素包括1989年的SLE活动(通过1989年最高的医生整体评估衡量,p = 0.004;1989年最高的狼疮活动指数(LAI)评分,p = 0.002;或1989年最高的系统性红斑狼疮疾病活动指数评分,p = 0.008)、1989年平均泼尼松剂量大于10 mg(p = 0.002)以及1989年存在神经精神性狼疮(p = 0.02)。除活动性SLE外的内科入院占另外27%的入院;其中一半(47%)是SLE及其治疗的并发症,冠状动脉疾病最为常见(占内科入院的21%)。感染占入院的14%。大多数感染为细菌性(90%)。1990年感染住院的危险因素包括1989年的活动性SLE(p = 0.03)、1989年平均泼尼松剂量大于10 mg(p = 0.04)、1989年使用免疫抑制药物(p = 0.003)、1989年的神经精神性狼疮(p = 0.02)以及1989年曾住院(p = 0.03)。

结论

在霍普金斯狼疮队列中住院很常见,活动性SLE(35%)、感染(14%,感染和/或活动性SLE;11%,单纯感染)和SLE的内科并发症(13%)是最常见的3个原因。

相似文献

1
Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort.系统性红斑狼疮患者住院的发生率及危险因素:霍普金斯狼疮队列的前瞻性研究
J Rheumatol. 1992 Oct;19(10):1559-65.
2
Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients.系统性红斑狼疮的感染与疾病活动:住院患者综述
J Rheumatol. 1991 Aug;18(8):1180-4.
3
All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre.来自加拿大大型转诊中心的系统性红斑狼疮全因住院治疗。
Rheumatology (Oxford). 2013 May;52(5):905-9. doi: 10.1093/rheumatology/kes391. Epub 2013 Jan 9.
4
Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.儿童期起病与成人期起病的系统性红斑狼疮疾病特征的差异。
Arthritis Rheum. 2008 Feb;58(2):556-62. doi: 10.1002/art.23204.
5
High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.系统性红斑狼疮中不进行干细胞移植的大剂量环磷酰胺治疗
Arthritis Rheum. 2003 Jan;48(1):166-73. doi: 10.1002/art.10752.
6
Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.一组系统性红斑狼疮患者中抗磷脂抗体与静脉血栓形成的发生率
J Rheumatol. 2002 Dec;29(12):2531-6.
7
Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus.系统性红斑狼疮女性患者颈动脉斑块的患病率及危险因素
Arthritis Rheum. 1999 Jan;42(1):51-60. doi: 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D.
8
Pancreatitis in systemic lupus erythematosus: frequency and associated factors - a review of the Hopkins Lupus Cohort.系统性红斑狼疮相关性胰腺炎:频率及相关因素——对霍普金斯狼疮队列的回顾。
J Rheumatol. 2010 Feb;37(2):341-5. doi: 10.3899/jrheum.090829. Epub 2009 Dec 23.
9
Reproductive factors and risk of systemic lupus erythematosus: nationwide cohort study in Denmark.生殖因素与系统性红斑狼疮风险:丹麦全国队列研究
J Rheumatol. 2009 Sep;36(9):1903-9. doi: 10.3899/jrheum.090002. Epub 2009 Jun 30.
10
Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus.系统性红斑狼疮患者中冠状动脉疾病的住院情况。
Arthritis Rheum. 2003 Sep;48(9):2519-23. doi: 10.1002/art.11241.

引用本文的文献

1
Long Term Outcomes of Anti-COVID-19 Vaccines in Patients with Systemic Lupus Erythematosus: A Multicentre Study.系统性红斑狼疮患者接种抗COVID-19疫苗的长期结局:一项多中心研究
Vaccines (Basel). 2025 Jul 8;13(7):735. doi: 10.3390/vaccines13070735.
2
Medication-related hospitalisations in patients with SLE.系统性红斑狼疮患者与药物相关的住院情况。
Lupus Sci Med. 2025 Jan 30;12(1):e001362. doi: 10.1136/lupus-2024-001362.
3
Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients.
系统性红斑狼疮患者因疾病活动和感染导致首次住院的预测因素。
Lupus. 2024 Nov;33(13):1492-1501. doi: 10.1177/09612033241283551. Epub 2024 Sep 11.
4
A case report of massive pulmonary tuberculosis and newly diagnosed systemic lupus erythematosus with complications.一例伴有并发症的重症肺结核合并新诊断系统性红斑狼疮的病例报告
Clin Case Rep. 2024 Sep 4;12(9):e9407. doi: 10.1002/ccr3.9407. eCollection 2024 Sep.
5
The prevalence of neutropenia and association with infections in patients with systemic lupus erythematosus: a Swedish single-center study conducted over 14 years.系统性红斑狼疮患者中性粒细胞减少症的流行情况及其与感染的相关性:一项在瑞典单中心进行的超过 14 年的研究。
Rheumatol Int. 2024 May;44(5):839-849. doi: 10.1007/s00296-024-05566-9. Epub 2024 Mar 19.
6
Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?使用皮质类固醇和免疫抑制剂是否会增加系统性红斑狼疮患者感染 COVID-19 的风险?
Lupus Sci Med. 2023 Oct;10(2). doi: 10.1136/lupus-2023-000961.
7
Epidemiology of systemic lupus erythematosus in Korea.韩国系统性红斑狼疮的流行病学
J Rheum Dis. 2023 Oct 1;30(4):211-219. doi: 10.4078/jrd.2023.0037. Epub 2023 Sep 11.
8
Glucocorticoid treatment in SLE is associated with infections, comorbidities and mortality-a national cohort study.系统性红斑狼疮患者应用糖皮质激素治疗与感染、合并症和死亡率相关:一项全国性队列研究。
Rheumatology (Oxford). 2024 Apr 2;63(4):1104-1112. doi: 10.1093/rheumatology/kead348.
9
Comparative Risks of Infection With Belimumab Versus Oral Immunosuppressants in Patients With Nonrenal Systemic Lupus Erythematosus.比较非肾脏系统性红斑狼疮患者使用贝利尤单抗与口服免疫抑制剂的感染风险。
Arthritis Rheumatol. 2023 Nov;75(11):1994-2002. doi: 10.1002/art.42620. Epub 2023 Oct 8.
10
Short-term prognostic analysis of patients with systemic lupus erythematosus co-infection and comparison of mNGS and conventional microbiological test results.系统性红斑狼疮合并感染患者的短期预后分析及 mNGS 与传统微生物学检测结果比较
Front Cell Infect Microbiol. 2023 Mar 27;13:1131258. doi: 10.3389/fcimb.2023.1131258. eCollection 2023.